Sysmex Corporation (SSMXF)
PNK · Healthcare · Medical Devices
Closing price as of 2026-10-27 · Source: TEK2day Finance
Key Metrics
About Sysmex Corporation
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte counts; coagulation, blood gas/ electrolyte/ urinalysis, cells/ microorganisms, including particle counter/analyzer CDA-1000/1000B, an equipment which is capable of counting cells, yeast, algae, bacteria, and others. The company serves national and other public hospitals, general hospitals, universities, research institutes, other medical institutions, etc. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
Quarterly Financials (JPY)
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 126.8B | 128.6B | 138.8B | 130.7B |
| Gross Profit | 68.1B | 65.1B | 68.0B | 66.3B |
| Operating Income | 22.3B | 15.7B | 14.7B | 14.8B |
| Net Income | 14.5B | 14.7B | 1.8B | 8.7B |
| Diluted EPS | JPY 14.17 |
Annual Financials (JPY)
| Metric | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 410.5B | 461.5B | 508.6B | 500.0B |
| Gross Profit | 216.1B | 242.5B | 272.0B | 255.7B |
| Operating Income | 76.0B | 80.6B | 90.8B | 63.4B |
| Net Income | 45.8B | 49.6B | 53.7B | 35.5B |
| Diluted EPS | JPY 72.91 | JPY 79.24 | JPY 86.05 | JPY 56.89 |